A new grouping of patients in obinutuzuma, using the new large spread B-cell lymphoma (dbcl)

摘要

The invention relates to a humanized class II anti-CD20 antibody (obintuzumab or its functional equivalent), which comprises: (a) a variable heavy chain region as shown in SEQ ID No.1 or as shown in SEQ ID No.5 (residual carbamate 1-119) and a variable light chain region as shown in. e. In SEQ ID No.2 or SEQ ID No.6 (residual carbamate 1 to 115);O (b) a heavy chain variable region, encoded by at least 80% of the nucleic acid sequence number 3 or SEQ ID No.7, and encoded by at least 80% of the nucleic acid sequence number 4 or SEQ ID No.8. This antibody leads to cell proliferation and cell decay dependent antibody (ADCC),An antibody dependent (ADCP) - dependent increase in blood glucose and an increase in the affinity of the RIII (γ) Fc receptor are useful in the treatment of large diffuse B-cell lymphoma (dbcl).